A 4-year-old boy from Delhi presents with intense pruritus and erythematous patches on his face, neck, and flexural surfaces (antecubital and popliteal fossae) for the past 8 months. His mother reports that symptoms worsen in winter and improve during monsoon. On examination, he has lichenification, excoriations, and a positive Dennie–Morgan fold. His serum IgE is elevated at 450 IU/mL. Skin prick testing shows reactivity to dust mites and pollen. What is the most appropriate first-line pharmacological management for acute flare control in this child?

Explanation

## Diagnosis and Clinical Context **Key Point:** This is a classic presentation of atopic dermatitis (AD) in a child with age-appropriate distribution (face, neck, flexures), seasonal variation, elevated IgE, positive atopy markers, and lichenification indicating chronic disease. ## First-Line Management Hierarchy in Pediatric AD The stepwise approach to AD management follows a pyramid: ```mermaid flowchart TD A[Atopic Dermatitis Flare]:::outcome --> B[Emollients + Skin Care]:::action B --> C{Mild Flare?}:::decision C -->|Yes| D[Topical Corticosteroid]:::action C -->|No| E{Moderate-Severe?}:::decision E -->|Yes| F[Potent TCS + Tacrolimus]:::action E -->|No| G[Systemic Therapy]:::action D --> H[Hydrocortisone 1% or Mild TCS]:::action F --> I[Fluticasone/Mometasone + Tacrolimus]:::action G --> J[Prednisolone/Dupilumab]:::urgent ``` ## Why Topical Hydrocortisone 1% is Correct | Feature | Rationale | |---------|----------| | **Age appropriateness** | Hydrocortisone (mild TCS) is safest for facial/neck skin in children <12 years | | **Flare severity** | Erythema + pruritus without systemic symptoms = mild-to-moderate flare | | **First-line status** | WHO/AAD/IADVL guidelines recommend TCS as first-line for acute flares | | **Potency selection** | Face/neck require mild potency; potent TCS risk atrophy in thin-skin areas | | **Frequency** | Twice daily dosing allows rapid symptom control (48–72 hours) | **High-Yield:** In pediatric AD, **mild TCS (hydrocortisone, methylprednisolone acetate) for face/neck** and **moderate TCS (mometasone, fluticasone) for trunk/flexures** are first-line. Systemic corticosteroids are reserved for severe, widespread flares refractory to topical therapy. ## Why Other Options Are Suboptimal **Tacrolimus 0.03%:** While effective for steroid-sparing maintenance and facial AD, it is NOT first-line for acute flare control. It is reserved for: - Steroid-sparing therapy in chronic AD - Facial/intertriginous disease (to avoid TCS atrophy) - Second-line if TCS fails **Oral cetirizine + emollients:** Antihistamines have minimal efficacy in AD (pruritis is not primarily histamine-mediated). Emollients alone are insufficient for active flares; they are adjunctive. **Systemic prednisolone:** Reserved for: - Severe, widespread flares unresponsive to topical therapy - Acute exacerbations with systemic features - Risk of rebound flares upon withdrawal; not first-line **Clinical Pearl:** The **Dennie–Morgan fold** (extra fold of skin below lower eyelid) is a clinical sign of chronic AD and indicates need for proactive maintenance therapy, but does not change acute flare management. **Key Point:** Always combine topical corticosteroids with emollients (not shown as separate option here, but assumed as baseline care). Emollients should be applied immediately after bathing to trap moisture.